SBIR/STTR Research Award

Design and synthesis of a next generation glycobiology toolbox for cell surface labeling

Award identifier 1f4d411fc8ada75e8b10abcee700b078ae1d9f1fae2a256f8a26d3d91d9198deAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$290,927

Program and phase

SBIR · Phase I

Award year

2023

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CHEMILY, LLC
Proposal award date
2023-04-01
Contract end date
2023-12-31
UEI
JJW4GNPDZCW4
Solicitation number
PA22-176
Topic code
300

Research abstract

The cell membrane is the interface by which a cell interacts and communicates with its surroundings, including nearby cells, proteins, and antibodies. Membranes of healthy cells are often modified in diseased states, providing an external means to distinguish between morphologically similar cells. Often, diseased cells display modified carbohydrates and glycans on their cell membranes. Recent developments in enzyme-mediated cell surface engineering provide promising routes for labeling these modifications in different cell types. The approach known as chemoenzymatic glycan labeling combines glycosyltransferases and unnatural nucleotide sugar donors equipped with chemical tags to directly label specific surface glycans within biological samples. Recently, this single step labelling approach has been successfully used with fucosyltransferase and GDP-fucose equipped with biotin tags. Compared with other genetic and metabolic techniques, this method of labeling living cells is a more direct, simpler procedure with a faster turnover cycle. It has also been shown to be generally applicable to murine tumor models, and thus has a high potential for transfer to a clinical setting. While published reports have focused on a low number of GDP-fucose labels, the high potential of this method is limited only by the availability of nucleotide sugar labels paired with acceptable glycosyltransferases. In order to accelerate medical advances based on cellular interactions, there is an urgent need to expand the availability of nucleotide sugar labels and transferases that can be used by this method.The goal of our Phase I project is to meet this need and provide non-expert users with a platform for labeling glycans on the membranes of their choice cells. Meeting this goal will expand the availability of glycoengineering reagents and methods beyond published studies. In Aim 1, we will create 12 new nucleotide sugar derivatives with labels. Derivatives will be based on successful studies of GDP-fucose, and expanded to CMP-sialic acid. Nucleotide sugars will be modified through click-chemistry with a fluorescent dye, biotin, or photoprobe label. In Aim 2, we will screen and optimize glycosyltransferases capable of attaching labeled nucleotide sugars to glycan substrates and cell surfaces. We will advance 10 kits that combine the most effective combinations of label and transferase, along with standard operating procedures and conditions that are accessible to end users. Users may then label membranes with fluorescent tags for cell surface imaging, biotin for cell selection, or photoprobes for crosslinking. Data will support Phase II efforts to compare this method to existing technologies and probe specific cell types.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2013–2023). Reported award amounts total $3,205,020. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.